Progress in molecularly targeted therapies for acute myeloid leukemia

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Genetic abnormalities including specific point mutations have recently been confirmed by applying comprehensive genome sequencing analyses. Molecular targeting therapies, which focus on the mutated proteins and over-expressed proteins in acute myeloid leukemia (AML) cells, are now being developed in clinical studies and/or based on in vitro analyses. This manuscript summarizes the genetic abnormalities in AML cells and some of the current molecular targeting therapies including FLT3 inhibitors (e.g. AC220; Quizartinib), Polo like kinase 1 (PLK1) inhibitors (e.g. BI-6727; Volasertib), IDH2 inhibitors (e.g. AG-221), and XPO1 inhibitors (e.g. KPT-330; Selinexor).

Original languageEnglish
Pages (from-to)130-138
Number of pages9
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Issue number2
Publication statusPublished - 01-02-2015
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Progress in molecularly targeted therapies for acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this